Aflac Incorporated (NYSE:AFL), the $55.44 billion market cap insurer, announced Tuesday that its Board of Directors has authorized the purchase of up to 100 million shares of its common stock, adding to the 30.9 million shares that remained available under its previous November 2022 authorization. According to InvestingPro data, management has been consistently aggressive with share buybacks. The new authorization brings the total number of shares available for repurchase to approximately 130.9 million, according to a company press release. Aflac indicated that it plans to conduct the share repurchases 'from time to time in open market or negotiated transactions, depending on market conditions.' Aflac, a Fortune 500 company that specializes in supplemental insurance, has established itself as a significant player in both U.S. and Japanese markets. In the United States, the company is the leading provider of supplemental health insurance products, while Aflac Life Insurance Japan leads in cancer and medical insurance policies in force in Japan. The company has maintained a presence on Fortune’s World’s Most Admired Companies list for 24 years and has been included in Ethisphere’s World’s Most Ethical Companies ranking for 19 consecutive years. The announcement comes as part of Aflac’s ongoing capital management strategy. The company did not specify a timeline for completing the newly authorized share repurchases. In other recent news, Aflac Inc. reported its second-quarter earnings for 2025, exceeding analysts’ expectations with an adjusted earnings per share (EPS) of $1.78, while the forecast was $1.70. However, the company’s revenue fell short, coming in at $4.16 billion compared to the anticipated $4.33 billion. Despite this revenue miss, investor sentiment remained positive, as reflected in the stock’s rise. Aflac’s strategic initiatives and strong performance in Japan were significant contributors to these earnings results. These developments highlight the company’s ability to navigate challenges and capitalize on opportunities in key markets. The earnings report underscores Aflac’s ongoing efforts to strengthen its financial position. Analysts and investors will likely keep a close watch on how Aflac continues to execute its strategies in the coming quarters.

Aflac authorizes purchase of 100 million additional shares By Investing.com

Aflac Incorporated has authorized the purchase of up to 100 million additional shares of its common stock, bringing the total available for repurchase to approximately 130.9 million shares. The company plans to conduct these repurchases from time to time through open market or negotiated transactions, depending on market conditions. The move is part of Aflac's ongoing capital management strategy. In its second-quarter 2025 earnings, Aflac reported adjusted earnings per share of $1.78, exceeding the $1.70 forecast, although revenue fell short at $4.16 billion versus the expected $4.33 billion. Despite the revenue shortfall, investor sentiment remained positive, with the stock rising. Aflac continues to perform strongly in both the U.S. and Japanese markets, maintaining its position as a leading provider of supplemental health insurance in the U.S. and in cancer and medical insurance in Japan. The company has been recognized on Fortune’s World’s Most Admired Companies list for 24 years and in Ethisphere’s World’s Most Ethical Companies ranking for 19 consecutive years.